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Abstract
Background: Prevalence of type 2 diabetes (T2D) is increasing worldwide. T2D prevention by lifestyle intervention is
effective. Pragmatic scalable interventions are needed, with evidence to efficiently target and monitor such interventions.
We report pooled analyses of data from three European trial cohorts: to analyse T2D incidence, sustained weight loss and
utility of risk predictors.
Methods: We analysed data on 749 adults with impaired glucose tolerance (278 men and 471 women, mean age 56 years,
mean BMI 31 kgm22) recruited between 1993 and 2003, and randomised to intensive lifestyle intervention (I) or lifestyle
advice control (C). The intervention aimed to increase physical activity, modify diet, and promote weight loss$5%. Using
Cox-regression survival analysis, we assessed T2D incidence and the impact on T2D incidence of sustained weight loss, and
of baseline cut-point values of FINDRISC score, fasting plasma glucose (FPG), and HbA1c.
Results: Mean follow-up duration was 3.1 years. T2D was diagnosed in 139 participants (I = 45/379, C = 94/370). Cumulative
T2D incidence was 57% lower in the intervention compared with the control group (HR 0.42 (95% CI 0.29 to 0.60) P,0.001).
Participants with $5% weight loss at one year had 65% lower T2D incidence (HR 0.35 (95% CI 0.22 to 0.56) P,0.001);
maintaining $5% weight loss for two and three years further reduced T2D incidence. Recommended cut-points to identify
those at high risk for T2D would have identified different proportions of European Diabetes Prevention Study (EDIPS)
participants with similar hazard-ratios for intervention effect.
Conclusions: Pooled analysis of EDIPS trial data reinforces evidence for T2D prevention by lifestyle intervention. Analysis
showed the preventive effect of $5% weight loss, especially if maintained long term, which has utility for intervention
monitoring. Analysis of proposed cut-points demonstrates difficulties in balancing risk and benefit, to efficiently target
interventions and suggests evidence is needed to define clinical policy.
Trial registrations: The Finnish Diabetes Prevention study, Helsinki, Finland: ClinicalTrials.gov; NCT00518167; The SLIM
diabetes prevention study, Maastricht, The Netherlands: Clinical Trials.gov; NCT00381186; The EDIPS-Newcastle diabetes
prevention study, Newcastle upon Tyne, UK: International Standard Randomised Controlled Trial Number; ISRCTN15670600.
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Introduction
Diabetes is predicted to affect 552 million people globally by
2030. [1] Type 2 diabetes (T2D) accounts for 90% of cases,
resulting in substantial disability, premature mortality, and
healthcare costs, [1] and its prevention is an important public
health challenge. Genetic predisposition contributes to T2D risk,
but disease development is strongly linked to excess body weight
and lifestyle factors including diet and inactivity. [1] Both
population level interventions to address obesity prevalence and
interventions targeting individuals at high-risk of T2D are needed.
[2–4] Impaired glucose tolerance (IGT) is a precursor of T2D that
identifies individuals at high-risk [1].
The Finnish Diabetes Prevention Study (DPS) randomised
controlled trial (RCT) demonstrated the efficacy of lifestyle
intervention to prevent T2D in adults with IGT. [5] Subsequent
RCTs have demonstrated efficacy in other populations. [2,6] The
European Diabetes Prevention Study (EDIPS) collaboration
applied the DPS protocol in other European countries. The
EDIPS trial cohorts comprised the DPS study in Finland; [5] the
SLIM study in Maastricht, The Netherlands; [7] and the EDIPS-
Newcastle study in Newcastle upon Tyne, UK. [8] All three
EDIPS cohorts used a common protocol with similar intervention
goals and study design, although some variability in local
intervention delivery was permitted to enhance cultural accept-
ability. Details of the individual RCTs contributing to the pooled
EDIPS data-set have been published [5,7,8].
A vital prerequisite in achieving reduction in T2D globally is to
develop scalable, transferrable and cost-effective T2D prevention
interventions that can be delivered in routine health care. [2,9]
The Finnish Development Programme for the Prevention and
Care of Diabetes (DEHKO) and associated T2D prevention plan
(FIN-D2D) is leading the way. [10,11]. The UK National Institute
for Health and Clinical Excellence (NICE) has published guidance
for ‘Preventing type 2 diabetes: risk identification and interven-
tions for individuals at high-risk’. [2,4] The EDIPS RCTs
recruited adults with IGT, but measuring glucose tolerance is
impractical and too costly for large scale screening. [2] Instead,
translational studies have used prospective risk scores, such as the
Finnish Diabetes Risk Score (FINDRISC), [12] to identify high-
risk individuals. However risk scores are population specific,
provide valid individual risk estimates only when all data items are
available and accurate, and cannot diagnose T2D. The NICE
Programme Development Group for T2D prevention has
advocated a two-stage screening strategy, using a risk score
followed by a blood test for fasting plasma glucose (FPG) or
glycated haemoglobin A1c (HbA1c), to confirm high-risk. [2] This
is a pragmatic strategy, but RCT evidence for effective and
sustained T2D prevention [13,14] is derived from at-risk
populations identified by IGT and extrapolation to other high
risk groups may not be warranted. In addition, many translational
studies use weight loss at one year follow-up as the primary
outcome. [15] The effect of achieving a weight loss goal at Year 1,
and subsequent maintenance, has not been demonstrated.
Percentage weight loss provides an easily-measured self-regulation
goal for intervention participants [2] and the number of
participants who achieve a pre-determined percentage weight loss
could offer a useful key performance indicator for intervention
monitoring.
The EDIPS RCTs aimed to evaluate the efficacy of similar
lifestyle intervention in three European populations. In this paper,
we report pooled analysis of data from the EDIPS cohorts. Weight
loss $5% was an intervention goal [16] and, in this paper, we
assessed the impact of sustained weight loss on T2D incidence. In
addition, to inform future research and policy, we assessed the
utility of alternative risk identification parameters and different cut
point values in predicting outcomes in the EDIPS cohorts.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Ethics Statement
Ethical approvals were given for the DPS by the ethics
committee of the National Public Health Institute, Helsinki,
Finland; for the SLIM study by the Medical Ethical Review
Committee of Maastricht University; and for EDIPS-Newcastle by
the Newcastle and North Tyneside NHS research ethics commit-
tee. All participants gave their written informed consent before
starting the study.
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Trial Design
Details of the EDIPS protocol were similar in each country,
have been published for each trial cohort [5,7,8] and are described
briefly here.
Randomisation and Masking
Participants were allocated at random in a 1:1 ratio to an
intensive lifestyle intervention to promote increased physical
activity and dietary modification or to a minimal lifestyle advice
control group. For the DPS and EDIPS-Newcastle (but not SLIM)
the randomisation lists were generated and supplied by the
coordinating centre in Helsinki and staff who made baseline
measurements had no access to the randomisation lists. Neither
staff delivering the intervention nor participants were masked to
the study arm.
Follow-up
Participants received a clinical assessment, including an Oral
Glucose Tolerance Test (OGTT), anthropometric and blood
biochemistry measurements, at baseline and annually thereafter.
In addition they were asked to complete physical activity and
dietary intake diaries. Measurement details, timelines and
locations have been published. [5,7,8,17] In March 2000,
independent statistical analysis of the DPS data led to the end-
point committee’s decision to end the DPS trial. Some participants
completed six years in the study [5].
Participants
We included adults over 40 years with BMI$25 kgm22 (or
family history of T2D in the SLIM study) and with IGT, defined
as plasma glucose concentration 7?8 to 11?0 mmoll21 (140 to
199 mg/dl) two hours after a standard fasting Oral Glucose
Tolerance Test (OGTT) (glucose load 75 g). [18] Exclusion
criteria were diagnosis of T2D, chronic illness making participa-
tion in moderate physical activity impossible and medication (e.g.
corticosteroids) that would compromise the intervention.
Interventions
Intervention goals were based on a common protocol and
comprised: weight reduction $5%, moderate physical activity for
at least 30 minutes per day or equivalent (assessed as at least 30
minutes at level 5 MET/hours) and improved dietary quality, with
increased fibre, reduced fat and reduced saturated fat intake. The
DPS and EDIPS-Newcastle goals for fat intake were ,30% total
fat and ,10% saturated fat, whilst the SLIM study goals were in
accordance with the Dutch guidelines (Dutch Nutrition Council)
that advised 30 to 35% total fat intake with ,10% saturated fat
[19].
Intervention delivery centred on individual counselling, includ-
ing motivational interviewing. [20] Physical activity and food
diaries, completed quarterly, facilitated personalised advice
delivered by trained health professionals. Supervised physical
activity sessions and access to leisure facilities were promoted.
Control Condition
Control group participants were given brief written and verbal
information about a healthy diet and the benefits of physical
activity.
Outcomes
The primary outcome was impact of lifestyle intervention on
T2D incidence. Diagnosis of T2D was determined at annual
follow-up using a standard OGTT with 2 hour venous plasma
glucose $11?1 mmoll21 or FPG$7?8 mmoll21 in accordance
with WHO criteria. [18] In the DPS and EDIPS-Newcastle
cohorts, a repeat measure confirmed the diagnosis and was a study
end-point. In the SLIM cohort, diabetes diagnosis was based on a
single OGTT. Secondary outcomes were weight loss, increased
physical activity and improved dietary quality.
Sample size was determined for the DPS with 80% power and
95% significance to detect 30% reduction of T2D incidence in the
intervention group compared with the control group. This
calculation was based on the assumption that 28% of adults with
IGT would progress to T2D in five years. The DPS, EDIPS-
Newcastle and SLIM cohorts contributed to a planned total of 750
European participants [21].
Data Analysis
For analysis of the pooled EDIPS data-set we used SPSS (IBM
SPSS inc. Version 17). We used independent t-tests and Chi-
squared tests to compare variables at baseline and Cox-regression
survival analysis to assess risk of developing T2D, with T2D
incidence as the explanatory variable controlling for trial cohort
(Finland, The Netherlands, and The UK). For pooled analysis of
the main trial outcome, we used RevMan (The Cochrane
Collaboration Review Manager 5.1) to conduct meta-analysis
assessing risk ratios using Mantel-Haenszel, random effects and
Tau2 variance measure.
The EDIPS data-set includes cases with baseline
FPG$7?0 mmoll 21 or HbA1c $6?5%. In 2012, these values
would be in the diabetic range due to recent changes in WHO
diagnostic criteria. [22,23] We therefore analysed a sub-set of the
EDIPS data with these cases removed as a sensitivity analysis.
For explanatory analysis of weight loss maintenance, we pooled
intervention and control group data. In separate analyses, we
compared those who achieved $5% weight loss at 12 months,
those who achieved this goal at 12 months and maintained it at 24
months, and those who achieved this goal at 12 months,
maintained it at 24 months and again at 36 months, with those
who did not achieve these goals.
We analysed values of FINDRISC score, [12] FPG and HbA1c
at baseline in relation to EDIPS outcomes. We used Cox-
regression to analyse the effect of intervention on risk of
developing T2D in EDIPS sub-sets defined by FPG and HbA1c
cut-points recommended by NICE [22] and the American
Diabetes Association (ADA) [24] and, for FPG, recommended
by WHO [22] (the WHO expert group concluded that there was
insufficient evidence to recommend HbA1c cut-points for non-
diabetic hyperglycaemia [23]), as well as combinations of risk score
and blood tests ranges.
Results
Incidence of T2D
In the three European Diabetes Prevention Study (EDIPS)
cohorts we recruited a total of 771 participants and followed them
up for a mean duration of 3?1 years (maximum 6 years). [5,7,8]
For the analyses presented here, we included 749 (DPS n= 522,
SLIM n=125, and EDIPS-Newcastle n = 102) with IGT at
Figure 1. CONSORT Flow chart - recruitment by trial cohort and progress of participants. The flow chart refers to participants in the EDIPS
study with impaired glucose tolerance at baseline.
doi:10.1371/journal.pone.0057143.g001
European Diabetes Prevention Study
PLOS ONE | www.plosone.org 4 February 2013 | Volume 8 | Issue 2 | e57143
baseline (22 participants from the SLIM study with 2 hour plasma
glucose value .11?0 moll21 were excluded). Details of the
recruitment dates, randomisation and trial progression are shown
in Figure 1. Baseline characteristics included mean (SD) age 55?6
(8?1) years, BMI 31?2 (4?9) kgm22, and FINDRISC score 14?0
(4?2). There were no statistical differences in any of the baseline
measures between intervention and control groups (Table 1). T2D
was diagnosed in 139 participants (I = 45, C= 94). The absolute
incidence of T2D was 38?3 per 1000 person-years in the
intervention group and 81?9 per 1000 person-years in the control
group. On average, 7?4 persons were treated for a mean of 3?1
years to prevent one case of T2D (equivalent to a number needed
to treat (NNT) of 22?9 for one year). In meta-analysis of pooled
data from the three EDIPS study cohorts, there was no statistically
significant heterogeneity between studies (Figure 2). Meta-analysis
resulted in a pooled risk-ratio of 0?47 (95% CI 0.34–0.65).
Cox-regression analysis, controlling for trial cohort, suggested
the cumulative incidence of T2D was 57% lower in the
intervention than in the control group (hazard ratio 0?43 (95%
CI 0?30 to 0?61); P,0?001) (Figure 3) (this differs from the risk
ratio above (Figure 2), which does not account for survival). In sex-
specific analyses, cumulative incidence of T2D was 63% lower for
males (hazard ratio 0?37 (95% CI 0?21 to 0?65); P,0.001) and
52% lower for females (hazard ratio 0?48 (95% CI 0?30 to 0?77);
P,0.001).
Cox-regression analysis of a sub-set (n = 632) in which cases
having a single baseline value of FPG$7?0 mmoll21 or HbA1c
$6?5% were removed, [23] showed 62% reduction in T2D risk in
the intervention group compared with the control group (hazard
ratio 0?38 (95% CI 0?25 to 0?60), P,0?001).
Impact of Weight Loss Maintenance
In the intervention group, 144 (38%) achieved $5% weight loss
at Year 1, 105 (28%) maintained this at Year 2 and 86 (23%) at
Year 3; whilst in the control group 50 (14%) achieved$5% weight
loss at year one, 26 (7%) maintained this at year two, and 18 (5%)
at year three (Chi-Squared tests, p,0?0001 for difference in the
proportions achieving weight loss between intervention and
control groups at each time point). Cox-regression analysis of
pooled (intervention and control group) data, showed that
participants who achieved $5% weight loss at year one had
64% lower T2D incidence (hazard ratio 0?36 (95% CI 0?22 to
0?56); P,0?001), those who maintained this at year two had 79%
lower T2D risk (hazard ratio 0?21 (95% CI 0?09 to 0?49)
P,0?001), and those who maintained this at year three had 89%
lower T2D risk (hazard ratio 0?11 (95% CI 0?04 to 0?35)
P,0?001) (Figure 4). There were no statistically significant
differences in any of the baseline variables (as listed in Table 1)
for those who met, or did not meet, these weight loss goals, other
than a slightly lower baseline age for those achieving the weight
loss goal in the first year (54?4 years compared with 56?0 years;
P = 0?02). Analysis of effects of weight loss using only intervention
group data produced similar results.
Cases achieving $5% weight loss at Year 1 numbered 194
(I = 144, C= 50). Results of Cox- regression survival analysis of
T2DM incidence in the intervention compared with the control
group showed HR 0.41(95% CI 0.16 to 1.03) p = 0.06 (B (SE)
20.90 (0.47)).
Consideration of Risk Score and Hyperglycaemia Cut-
point Values for Risk Identification
The number of EDIPS participants (all of whom had IGT) who
would have been identified at baseline by FPG or HbA1c cut
points, as recommended by NICE, ADA and WHO, [2,22,23,25]
Table 1. Baseline characteristics: mean (SD) for continuous
variables and number (%) for categorical variables by trial arm.
Intervention
(n =379)
Control
(n =370)
Continuous variables Mean value (SD)
Age (years) 55?4 (8?0) 55?7 (8?2)
BMI (kgm22) 31?4 (5?0) 31?0 (4?8)
Waist (cm) 102?5 (11?2) 101?1 (10?4)
Hip (cm) 109?8 (10?3) 108?7 (10?8)
Weight (kg) 88?2 (14?8) 85?7 (13?6)
FINDRISC score11 14?2 (4?0) 14?0 (4?2)
Plasma glucose (mmol/l)
Fasting 6?0 (0?8) 6?0 (0?7)
60 minute 11?2 (2?0)a 11?1 (2?1)b
120 minute 8?8 (1?5) 8?7 (1?4)
Plasma insulin (mU/l)
Fasting 13?3 (7?8)c 12?8 (6?6)d
120 minute 84?7 (61?0)e 83?4 (56?7)f
Blood pressure (systolic) (mmHg) 139 (17) 137 (16)
Blood pressure (diastolic)(mmHg) 84 (9) 85 (9)
HbA1c (%) 5?7 (0?5)g 5?7 (0?5)h
Cholesterol (mmoll21 ) 5?5 (1?1)i 5?5 (1?0)j
Triglycerides (mmoll21 ) 1?7 (0?9)i 1?7 (0?8)j
HDL Cholesterol (mmoll21 ) 1?2 (0?3)i 1?2 (0?3)i
Categorical variables Number (%)
FINDRISC10 categories
Low ,7 6 (1.7) 14 (3.9)
Slightly elevated 7–11 93 (25.8) 85 (23.9)
Moderate 12–14 93 (25.8) 96 (27.0)
High 15–20 147 (40.7) 142 (39.9)
Very high .20 22 (6.1) 19 (5.3)
Data unavailable 18 (4.7) 14 (3.7)
Sex
Male 145 (38?3) 133 (35?9)
Female 234 (61?7) 237 (64?1)
Socio-economic status by educational level
Low 109 (28?8) 111 (29?9)
Medium 97 (25?6) 92 (24?8)
High 100 (26?4) 100 (27?0)
Data unavailable 73 (19?3) 67 (18?3)
Smoking status
Non-smoker 195 (51?5) 208 (56?1)
Current smoker 28 (7?4) 38 (10?2)
Data unavailable 156 (41?2) 124 (33?7)
an = 348.
bn = 330.
cn = 354.
dn = 348.
en = 351.
fn = 344.
gn = 370.
hn = 362.
In = 375.
jn = 364.
doi:10.1371/journal.pone.0057143.t001
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are shown in Table 2, with Cox-regression hazard ratios for
progression to T2D. Applying the proposed NICE guidance FPG
and HbA1c cut-points to the EDIPS cohort of adults with IGT
would have identified 66.8% (hazard ratio for progression to T2D
0?48 (95% CI 0?30 to 0?75) P,0.001) using FPG cut-points, but
only 17.9% (hazard ratio 0?34 (95% CI 0?16 to 0?72) using HbA1c
cut-points, whereas applying the ADA cut points for HbA1c would
have identified 42.2% (hazard ratio 0.38 (95% CI 0.19 to 0.76) of
EDIPS participants.
The number of EDIPS cases that would have been identified at
baseline by FINDRISC scores only, and combined with high-risk
FPG and HbA1c cut-points (mimicking the NICE guidance
proposed two stage screening process [2] ) are shown in Table 3.
Applying the FINDRISC cut point for moderate risk ($12) to the
EDIPS IGT cohort would have identified 69?3% (hazard ratio
0?42 (95% CI 0?20 to 0?51) P,0?001) of participants. A
combination of FINDRISC $12 and FPG 5?5 to 6?9 mmoll21
would have identified 49?4% (hazard ratio 0?48 (0?28 to 0?83)
Figure 2. Forest plot comparison of the three studies contributing to the EDIPS data-set.
doi:10.1371/journal.pone.0057143.g002
Figure 3. Progression to type 2 diabetes by trial arm.
doi:10.1371/journal.pone.0057143.g003
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P,0?001) whereas a combination of FINDRISC $12 and HbA1c
6?0 to 6?4% would have identified only 13?7% (hazard ratio 0?46
(95% CI 0?24 to 0?76) P= 0?08) of EDIPS participants [24].
Discussion
Principal Findings
The analysis presented here reinforces existing evidence for the
effectiveness of intensive lifestyle interventions to prevent T2D in
adults with IGT and provides evidence for the generalisability of
such interventions to European populations. Incidence of T2D
was reduced by 57% in the intervention group compared with the
control group. Explanatory analysis supported a $5% weight loss
goal, as advocated in the EDIPS protocol and by NICE, [2] in this
population and highlighted the importance of sustained weight loss
long term (.1 year). Recently proposed cut-points, using a risk
score (such as FINDRISC) and a blood test (FPG or HbA1c), to
identify individuals at high-risk would have identified substantially
different proportions of the EDIPS cohort of adults with IGT with
little variation in the hazard ratios for T2D incidence. This
analysis demonstrates the difficulties in efficiently identifying a
population for targeting interventions, where progressive risk and
evidence of potential to benefit, and intervention cost and capacity
to deliver, are appropriately balanced.
Strengths and Limitations of the Study
The EDIPS RCTs were conducted in three culturally different
populations, recruited over a 10 year period, and the consistency
of findings in different countries confirms the generalisability of the
lifestyle intervention originally designed for the DPS. We might
have expected the results of earlier diabetes prevention trials to
influence control group participants in the later EDIPS cohorts,
thus diluting the intervention effect, but there was little evidence
that this occurred.
EDIPS was conducted in a population of white European
ethnicity. In people of South Asian or African origin ethnicity,
T2D risk is elevated. Trials elsewhere have demonstrated efficacy
of lifestyle-based interventions for T2D prevention in these
populations, [26] but not so far in Europe, although trials among
South Asians living in Scotland, [27] London (G A Hitman
personal communication), Leicester (K Khunti personal commu-
nication) and Oslo [28] are underway.
The EDIPS protocol was common to all three cohorts. The
approach recognised the necessity for some local variation in
intervention delivery to achieve cultural resonance, but the
intervention goals, intensity and mode of delivery were similar.
Changes to the diagnostic criteria for T2D since the design of
EDIPS would have excluded some participants because they
would have been diagnosed with T2D during recruitment. [22,23]
However, analysis of a sub-set of cases with FPG$7?0 mmoll21
and HbA1C$6?5% removed did not alter the observed interven-
tion effect. Diagnosis of T2D at annual follow-up was based on
two hour venous plasma glucose values in an OGTT, [18] thus
some people were retained in the study with FPG$7?0 mmoll21
or HbA1C$6?5% who may have been diagnosed with T2D under
later criteria [22,23].
Figure 4. Progression to type 2 diabetes by weight loss achieved and maintained.
doi:10.1371/journal.pone.0057143.g004
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Comparisons with Other Studies
The 57% overall reduction in T2D incidence, with a NNT of
7?4, observed in EDIPS is in line with outcomes of other diabetes
prevention RCTs; meta-analysis of diet and/or exercise interven-
tion studies has shown a pooled hazard ratio of 0?51 (95% CI 0?44
to 0?60) and NNT of 6?4. [6] The recently published DE-PLAN-
CAT-PREDICE study [29] screened participants using FIN-
DRISC ($14) with subsequent OGTT to identify IFG or IGT
(WHO classifications). [22,23,29] Comparison of the lifestyle
intervention and standard care control groups showed risk
reduction of 36?5%. This lower effectiveness may reflect the
different study population (both different ethnicity and inclusion of
IFG identified high risk participants) or different intervention, or
both.
Recently data were published from a trial [30] where the
primary inclusion criterion was IFG (ADA range: FPG 5?6 to
6?9 mmoll21). [24] Overall, lifestyle intervention reduced T2D
risk by 44%. However, post-hoc sub-group analyses showed a
positive intervention effect in the IFG+IGT group (HR 0?41 (95%
CI 0?24 to 0.69), and IFG+HbA1c (HbA1c$5.6%) group (HR
0?24 (95% CI 0?12 to 0?48) only. In people with isolated IFG, who
comprised almost 60% of participants, no effect was observed
(17% non-significant increase in risk).
Weight loss is attractive for monitoring compliance with
interventions in routinely provided services, because it can be
easily and objectively measured. [2] By pooling data from
intervention and control groups for the analysis of weight loss
and T2D incidence, we sought to evaluate the utility of sustained
weight loss as an intermediate health outcome. Our explanatory
analysis of the EDIPS data set of adults of white European
ethnicity with IGT showed that achieving $5% weight loss at one
year reduced T2D incidence by 64%, with enhanced effect if
sustained at two or three years. Analysis of T2D incidence in those
achieving $5% weight loss at Year 1 suggests that additional
features of the intervention, such as increased physical activity and
improved nutrition, contributed to the reduction in T2D incidence
in these intervention group participants who also lost more weight
on average and retained their weight loss for longer.
Translational studies to date, with the exception of the GOAL
[31] and the DE-PLAN-CAT-PREDICE studies, [29] have had
follow-up of one year or less and have focussed on weight loss as an
intermediate health outcome. In a behaviour change RCT it is
impossible to exclude self-help within the control group, especially
where giving basic advice is ethically appropriate and regular
monitoring is required for those at risk. In our qualitative
evaluation, nested within the EDIPS-Newcastle trial, many
participants reported that it took two years to establish lifestyle
changes, suggesting that prolonged intervention may be required
to maximise weight loss maintenance and thus effective prevention
of T2D in those at high-risk [32].
Table 2. EDIPS cases identified by high-risk FINDRISC10 score or by cut-points for fasting plasma glucose (FPG) and glycated
Haemoglobin (HbA1c) as specified by NICE, ADA and WHO with risk statistics for intervention and control groups compared.
Moderate or lower risk High or greater risk
FNDRISC a 10 ,15 $15
EDIPS cases n (%) 387 (51?7)) 330 (44?1)
Hazard ratio (95% CI) P value and B(SE) for
intervention/control incidence
0?62 (0?37 to 1?05)
P = 0?072 20.5(0.3)
0?30 (0?20 to 0?51)
P,0?001 21.2(0.3)
FPG (mmoll21 ) Lower risk High risk Diabetic range
NICE ranges ,5?5 5?5 to 6?9 (99 to 125 mg/dl) $7?0
EDIPS cases n (%) 178 (23?8) 500 (66?8) 71 (9?5)
Hazard ratio (95% CI) P value and B(SE) for
intervention/control incidence
0?29 (0?12 to 0?71)
P = 0?007 21.2(0.5)
0?48 (0?30 to 0?75)
P,0?001 20.7(0.2)
ADA ranges ,5?6 5?6 to 6?9 (100 to 125 mg/dl) $7?0
EDIPS cases n (%) 214 (28?6) 464 (61?9) 71 (9?5)
Hazard ratio (95% CI) P value and B(SE)
for intervention/control incidence
0?26 (0?11 to 0?61)
P = 0?002 21.4(0.4)
0?51(0?32 to 0?82)
P = 0?005 20.7(0.2)
WHO ranges ,6?1 6?1 to 6?9 (110 to 125 mg/dl) $7?0
EDIPS cases n (%) 404 (53?9) 268 (35?8) 71 (9?5)
Hazard ratio (95% CI) P value and B(SE)
for intervention/control incidence
0?43 (0?24 to 0?77)
P = 0?005 20.8(0.3)
0?40 (0?22 to 0?71)
P = 0?002 21.0(0.3)
HbA1cb (%) Lower risk High risk Diabetic range
NICE and UK-NSC ranges ,6?0 6?0 to 6?4 (42–47 mmol/mol) $6?5
EDIPS cases n (%) 539 (72?0) 134 (17?9) 59 (7?9)
Hazard ratio (95% CI) P value and B(SE)
for intervention/control incidence
0?44 (0?27 to 0?68)
P,0?001 20.8(0.2)
0?34 (0?16 to 0?72)
P = 0?005 21.1(0.4)
ADA ranges ,5?7 5?7 to 6?4 (39–47 mmol/mol) $6?5
EDIPS cases n (%) 357 (47?7) 316 (42?2) 59 (7?9)
Hazard ratio (95% CI) P value and B(SE)
for intervention/control incidence
0?42 (0?26 to 0?70)
P,0?001–0.8(0.3)
0?38 (0?19 to 0?76)
P = 0?006 21.0(0.4)
doi:10.1371/journal.pone.0057143.t002
European Diabetes Prevention Study
PLOS ONE | www.plosone.org 8 February 2013 | Volume 8 | Issue 2 | e57143
The mean duration of the EDIPS trials was 3.1 years. Sustained
reduction in the incidence of T2D and the mediating effect of
weight loss have been shown in follow-up studies of the DPS [14]
and the US Diabetes Prevention Programme. [13] However, in
the Indian diabetes prevention study [33] a small weight loss in the
lifestyle intervention group at six months was not sustained and the
efficacy of weight loss for T2D prevention in people of South
Asian ethnicity remains unclear. Whilst reducing progression to
T2D in individuals at high-risk is important, there is also a need
for population level interventions to reverse the rise in obesity in
order to reduce T2D incidence [3].
Possible Mechanisms and Implications for Clinicians and
Policymakers
Translating evidence on the effectiveness of lifestyle intervention
for prevention of T2D in adults with IGT into cost-effective,
scalable interventions is challenging, especially in an era of
budgetary constraints.
Among these challenges is the efficient identification of
individuals at high-risk for effective, targeted intervention.
Translational studies focus on risk identification using prospective
risk scores. [34] For example, recent studies in Spain and Finland
have demonstrated the effect of lifestyle intervention where
recruitment was based on FINDRISC. [29,35] The screening
strategy proposed in the NICE guidance advocates a risk score
(such as FINDRISC), followed by a single blood test (either FPG
or HbA1c) to identify individuals at high T2D risk. [2] Applying
the cut-points proposed by NICE to the EDIPS cohort shows that
determining pragmatic, acceptable, low cost risk assessment with
high predictive value in identifying individuals with the greatest
potential to benefit from a T2D prevention intervention remains a
challenge. The optimum combination of risk-score and blood test
values for use in routine practice remains unclear and further
research is needed, including economic evaluation.
Our explanatory analysis suggests that sustained weight loss at
two and three years enhanced the intervention effect in the EDIPS
cohort. The most efficient duration and intensity of lifestyle
interventions to maintain weight loss [36] or to prevent T2D in
individuals at high-risk remain uncertain. [2] The economic
modelling undertaken for the NICE guidance development
suggests that screening and intervention for T2D prevention is
highly likely to be cost-effective, at a threshold of £10,000 per
quality adjusted life year (QALY) gained or less, but the authors
Table 3. EDIPS cases identified by FINDRISC10 and high risk cut-points for fasting plasma glucose (FPG) and glycated Haemoglobin
(HbA1c) as specified by NICE, ADA and WHO with risk statistics for intervention and control groups compared.
FINDRISC score cut-points
Moderate or greater risk ($12) High or greater risk ($15)
FINDRISC a score only
EDIPS cases n (%) 519 (69?3) 330 (44?1)
Hazard ratio (95% CI), P value and B(SE) for intervention/control incidence 0?43 (0?28 to 0.66) 0?30 (0?20 to 0?51)
P,0?001–0.8(0.2) P,0?001 21.2(0.3)
FPG (mmoll21 )
NICE high risk range (5?5 to 6?9)
EDIPS cases n (%) 354 (49?4) 224 (31?2)
Hazard ratio (95% CI), P value and B(SE) for intervention/control incidence 0?48 (0?28 to 0?83) 0?39 (0?20 to 0?78)
P = 0?008 20.9(0.4) P = 0?008 20.9(0.4)
ADA high risk range (5?6 to 6?9)
EDIPS cases n (%) 328 (45?7) 209 (29?1)
Hazard ratio (95% CI), P value and B(SE) for intervention/control incidence 0?51 (0.30 to 0.87) 0?41 (0?21 to 0?83)
P = 0?014 20.7(0.3) P = 0?007 20.9(0.4)
WHO high risk range (6?1 to 6?9)
EDIPS cases n (%) 198 (27?6) 62 (8?9)
Hazard ratio (95% CI), P value and B(SE) for intervention/control incidence 0?37 (0.23 to 0.64) 0?31 (0?13 to 0?73)
P = 0?003 21.0(0.3) P = 0?007 20.9(0.4)
HbA1c b (%)
NICE and UK-NSC high risk range (6?0 to 6?4)
EDIPS cases n (%) 96 (13?7) 62 (8?9)
Hazard ratio (95% CI) P value and B(SE) for intervention/control incidence 0?46 (0?19 to 1?10) 0?35 (0?12 to 1?00)
P = 0?08 20.8(0.4) P = 0?05 21.1(0.5)
ADA high risk range
EDIPS cases n (%) 227 (32?4) 158 (22?6)
Hazard ratio (95% CI),P value and B(SE) for intervention/control incidence 0?43 (0?24 to 0?76) 0?28 (0?13 to 0?59)
P = 0?004 20.8(0.3) P = 0?001 (21.2(0.4)
an = 717.
bn = 732.
doi:10.1371/journal.pone.0057143.t003
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acknowledge that the results are based on assumptions about
prevention effectiveness in individuals at high-risk identified by
criteria other than IGT. [2] Our analyses provide an indication of
intervention effectiveness, identified by a range of risk criteria.
Unanswered Questions and Future Research
The screening strategy proposed in the NICE guidance is
pragmatic, but our results show that the proposed cut-points for
HbA1c or FPG would identify different high-risk groups from those
with IGT. Research is needed to demonstrate the effectiveness of
lifestyle interventions on T2D incidence in populations identified
by different combinations and ranges of risk scores, FPG and
HbA1c values to identify the optimum risk assessment strategy in
terms of both patient benefit and cost-effectiveness. The incidence
and prevalence of T2D are socio-economically patterned and
there is therefore a need to develop lifestyle interventions for T2D
prevention that are accessible, culturally adapted and which
reduce social inequalities in outcomes. [37] However, the evidence
to date, including the present study, suggests that lifestyle
interventions are effective in diverse human populations.
Robust evaluations of pragmatic interventions for T2D preven-
tion are needed that can be delivered efficiently in the context of
routine health care provision and with sufficient duration for T2D
incidence to be the primary outcome.
Conclusion
The European Diabetes Prevention Study reinforces evidence
that intensive lifestyle intervention can prevent T2D in adults with
IGT, and provides evidence of wider generalisability in European
populations. Analyses demonstrated the preventive effect of $5%
weight loss, especially if maintained long term, which suggests the
utility of a $5% weight loss target for intervention monitoring.
Proposed blood test cut-points for high–risk would have
identified different proportions of the EDIPS cohort, with similar
intervention benefit. Identification of high-risk individuals for
provision of T2D prevention should consider risk profile along
with potential to benefit, as well as overall cost-effectiveness and
equity of outcomes.
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